HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have earned a consensus rating of “Hold” from the six brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $14.8667.

A number of brokerages have recently issued reports on HCM. Weiss Ratings raised HUTCHMED from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, July 17th. Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a report on Thursday, May 28th. The Goldman Sachs Group lowered their price objective on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, July 23rd. Finally, Bank of America cut their target price on shares of HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th.

HUTCHMED Stock Up 1.7%

HCM stock opened at $11.39 on Thursday. HUTCHMED has a 52-week low of $9.77 and a 52-week high of $18.79. The company has a current ratio of 4.96, a quick ratio of 4.83 and a debt-to-equity ratio of 0.05. The firm has a 50 day moving average price of $11.04 and a 200-day moving average price of $13.26.

HUTCHMED (NASDAQ:HCM) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.14 by ($0.09). The firm had revenue of $139.14 million during the quarter, compared to analysts’ expectations of $304.16 million. As a group, research analysts forecast that HUTCHMED will post 0.28 EPS for the current year.

Institutional Trading of HUTCHMED

A number of hedge funds have recently bought and sold shares of HCM. Renaissance Technologies LLC lifted its holdings in HUTCHMED by 3.0% in the fourth quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $1,798,000 after acquiring an additional 3,900 shares during the period. Goldman Sachs Group Inc. grew its stake in shares of HUTCHMED by 8.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after purchasing an additional 7,342 shares during the period. Dimensional Fund Advisors LP increased its position in shares of HUTCHMED by 157.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock valued at $746,000 after purchasing an additional 34,248 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of HUTCHMED by 19.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock valued at $377,000 after purchasing an additional 4,116 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in shares of HUTCHMED by 5.9% in the 3rd quarter. Bank of America Corp DE now owns 21,791 shares of the company’s stock worth $343,000 after purchasing an additional 1,209 shares during the period. Hedge funds and other institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.